Alvogen

Alvogen is a private, US-based pharmaceuticals company founded in 2009. Since 2015, it has been majority-owned by CVC Capital Partners and Temasek Holdings. Alvogen focuses on so-called 'difficult-to-make' generic drugs and injectables, and both produces its own products and markets the products of brand name pharmaceutical companies.

History

Alvogen was founded by Icelandic entrepreneur Róbert Wessman, who stepped down from his position as CEO of another generics company, Actavis, in order to found the company.

The first and still a central component of Alvogen is the 130-year old Norwich Pharmaceuticals, which was acquired by Wessman and his investors as a large-scale and certified manufacturing facility. From the early- to mid-2010s, Alvogen expanded rapidly through acquisitions. In Central and Eastern Europe it acquired companies and portfolios including Labormed in Romania. In East Asia, it acquired South Korea firms Kunwha and DreamPharma, and then operated them under the umbrella o
Lotus Pharmaceuticals
a Taiwan company it purchased in 2014 and which is listed on the Taipei Stock Exchange (1795.TT). In 2016, Alvogen expanded its US footprint with the acquisition of County Line Pharmaceuticals. The history of the growth of Alvogen is the subject of a Harvard Business School case study published in 2018.

In 2017, Alvogen was valued at $4 billion and had 2800 employees spread over thirty-five countries. Beginning in 2019, the company began to spin off its international operations and divisions, some of which had grown large enough to become standalone companies, and to focus on its US operations. Alvogen's Central and Eastern Europe operations were sold to Zentiva in 2019. In 2021, it spun off Lotus to a consortium of Innobic and Wessman's investment fun
Aztiq
which also bought Alvogen's Malta-based B2B licensing divisio
Adalvo
As of early 2025, Wessman was chairman of Alvogen, as well as of Lotus and Adalvo.

Alvogen was also the original investor i
Alvotech
a company founded by Wessman in 2013 that researches and manufactures biosimilars. Alvotech is based in Reykjavik and has four research and production sites across Europe and one in India. It is listed on Nasdaq (ticker
ALVO
and also trades o
Nasdaq Iceland
As of early 2025, it has several products approved in the US and Europe and markets globally through partnerships.

Pharmaceuticals

On its website, Alvogen lists dozens o
products it currently offers
on the US market. It specializes in products that are either difficult to make or are injectable or inhaled.https://www.alvogen.com/company It's injectables business is calle
Almaject

References

External links

Official website
{{Biotechnology industry in South Korea
Pharmaceutical companies based in New Jersey
Pharmaceutical companies established in 2009
Pharmaceutical companies of South Korea
Companies listed on the Korea Exchange
Temasek Holdings
CVC Capital Partners companies